**S. Figure 1 Correlation analysis.jpg**

Results of correlation analysis of a) DIPG samples with gene differential expressions (DE); b) DIPG samples with activation scores for gene expression regulators based on SNEA analysis with Elsevier Knowledge Graph. P01 - P38 numbers describe DIPG patients’ number from OpenPBTA.

**S. Figure 2 Combined Pathways of DIPG regulators.jpg**

Image of the model of gene expression regulators in DIPG based on SNEA analysis with Elsevier Knowledge Graph ([LINK](urn:agi-pathway:uuid-8980090e-f57e-4691-801d-692690e8ece4=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

**S. Figure 2.1 Pathways of DIPG regulators (simplified).jpg**

Simplified for better clarity image of the model of gene expression regulators in DIPG based on SNEA analysis with Elsevier Knowledge Graph.

**S. Figure 3 Cells biomarkers.jpg**

Gene expression regulators in DIPG linked with cells as their biomarkers (based on “CellExpression” and “Biomarker” types of relationship in Elsevier Knowledge Graph) ([LINK](urn:agi-pathway:uuid-2219d440-7237-4d5c-966c-9b08f3c58ff4=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

**S. Figure 4 TAMs biomarkers.jpg**

Gene expression regulators and genes with DE in DIPG linked with tumor-associated macrophages (TAMs) (based on “CellExpression” and “Biomarker” types of relationship in Elsevier Knowledge Graph) ([LINK](urn:agi-pathway:uuid-9e8cf494-1124-4d5e-bf04-b94efaf3f7b7=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

**S. Figure 5 EGFR Signaling.jpg**

Classical EGFR signaling. Genes with different expression (DEs) in DIPG are highlighted in red (over-expressed) and blue (down-expressed). Color saturation indicates the level of DEs ([LINK](urn:agi-pathway:uuid-3c2068d9-56c3-4aa5-8dbe-9d1b22a338b7=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1)).

**S. Figure 6 *TP53* and *EZH2* mRNA expression.jpg**

Levels of different expressions of *TP53* and *EZH2* genes and their scores as gene expression regulators distributed in DIPG tumors. Numbers 1- 38 describe DIPG patients’ number from OpenPBTA.

**S. Figure 7 *TP53* and *EZH2* targets.jpg**

Common expression targets for *TP53* and EZH2 genes predicted with Elsevier Knowledge Graph. Activation scores of gene expression regulators in DIPG are highlighted in red (active) and blue (non-active) ([LINK](urn:agi-pathway:uuid-2a54012d-a342-487c-8950-869872043a0b=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

**S. Figure 8 mut*TP53* effects on expression targets in DIPG.jpg**

Common expression targets for *TP53* and *EZH2* genes predicted with Elsevier Knowledge Graph. Genes with different expression (DEs) in DIPG are highlighted in red (over-expressed) and blue (down-expressed). Color saturation indicates the level of Des ([LINK](urn:agi-pathway:uuid-2a91e8ad-945b-4269-86d8-2c00dc40494a=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

**S. Figure 9 Hyaluronic Acid, CD44 and HMMR in Cancer Cell Invasion and Survival.jpg**

Role of CD44 signaling in cancer. Color saturation indicates the activation scores of regulators of gene expression (red - active; blue – inactive regulators) ([LINK](urn:agi-pathway:uuid-8008c83f-8e62-472e-aca9-c8b55df84c22=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1)).

**S. Figure 10 Clinical trials.**

61 clinical trials with drugs for DIPG registered at clinicaltrials.org with 20 drugs that have completed clinical trials phases 1 to 3 by March 2022.

**S. Figure 11 Anti-cancer drugs for DIPG patient P34.**

Predicted by SNEA drugs with anti-cancer activity for gene expression regulators of DIPG patient P034 which has deletion in *TP53* gene.

Figure B Active regulators for Sustaining Proliferative Signals Cancer Hallmark ([LINK](urn:agi-pathway:uuid-a0c8dc55-2c46-4ac2-bad4-2e0afafac1a6=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

Figure B Top Active Regulators ([LINK](urn:agi-pathway:uuid-708ae750-b97f-456f-92e5-8310d99f549c=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

Figure E Inactive regulators in NOTCH signaling ([LINK](urn:agi-pathway:uuid-b07f82d4-09a6-4705-8c69-db5d0a2e9b49=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

Figure D Combined pathway of top regulators and mutated genes ([LINK](urn:agi-pathway:uuid-9992fec7-2261-400f-9341-4ae24d1904d9=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

Figure D Combined pathway for top regulators and TP53 ([LINK](urn:agi-pathway:uuid-667e8f3d-b507-40ab-b32a-22fbde90a917=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

Figure F TP53 dependent targets in DIPG ([LINK](urn:agi-pathway:uuid-7e96084b-04c4-40ce-8b1e-e8873ec0efa5=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))

Figure I Drugs for mutTP53 ([LINK](urn:agi-pathway:uuid-708ae750-b97f-456f-92e5-8310d99f549c=urn:agi-pathway:uuid-bf674c6c-8e41-48ef-be52-dcbc3a817eb1))